| 0 (0%) | 09-27 11:15 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 60.29 | 1-year : | 63.77 |
| Resists | First : | 51.62 | Second : | 54.59 |
| Pivot price | 51.8  |
|||
| Supports | First : | 46.81 | Second : | 38.94 |
| MAs | MA(5) : | 50.54 |
MA(20) : | 51.79 |
| MA(100) : | 44.41  |
MA(250) : | 36.02 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 13.6 |
D(3) : | 20.4 |
| RSI | RSI(14): 47 |
|||
| 52-week | High : | 54.59 | Low : | 21.71 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BBIO ] has closed above bottom band by 17.3%. Bollinger Bands are 16.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 50.22 - 50.55 | 50.55 - 50.85 |
| Low: | 48.06 - 48.48 | 48.48 - 48.87 |
| Close: | 49.39 - 50.06 | 50.06 - 50.67 |
Thu, 25 Sep 2025
H.C. Wainwright Reiterates a Buy on BridgeBio Pharma (BBIO) - MSN
Wed, 24 Sep 2025
Retirement Income Solutions Inc Acquires Shares of 5,000 BridgeBio Pharma, Inc. $BBIO - MarketBeat
Tue, 23 Sep 2025
BridgeBio Pharma (BBIO): Evaluating Valuation in Light of New Acoramidis Clinical Data Reveal - simplywall.st
Tue, 23 Sep 2025
Strs Ohio Makes New Investment in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Mon, 22 Sep 2025
New Cardiovascular Outcomes Data: BridgeBio's Acoramidis Shows Impact on ATTR-CM Patient Survival - Stock Titan
Sat, 20 Sep 2025
Leerink Partners Maintains a Buy on BridgeBio Pharma (BBIO) With a $56 PT - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 191 (M) |
| Held by Insiders | 1.5136e+008 (%) |
| Held by Institutions | 4.7 (%) |
| Shares Short | 18,520 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.2373e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -120.8 % |
| Return on Assets (ttm) | -42 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 4 % |
| Gross Profit (p.s.) | 799.91 |
| Sales Per Share | 1.88648e+008 |
| EBITDA (p.s.) | 1.81472e+008 |
| Qtrly Earnings Growth | -4.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -656 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.7 |
| Dividend | 0 |
| Forward Dividend | 1.991e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|